Thomas F. Hiemstra

Thomas F. Hiemstra

Auto-generated profile, based on publicly available information

Thomas F. Hiemstra

Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in JAMA
Verified
Journal Article
Open access
PDF file
THThomas F. Hiemstra
Thomas F. Hiemstra
MWMichael Walsh
Michael Walsh
AMAlfred Mahr
Alfred Mahr
CSCaroline O. Savage
Caroline O. Savage
KGKirsten de Groot
Kirsten de Groot
Raoul BergnerRaoul Bergner
Raoul Bergner
Antineutrophil cytoplasmic antibodies (ANCAs) are frequently found in patients with Wegener granulomatosis and microscopic polyangiitis. Together, Wegener granulomatosis and microscopic polyangiitis are considered ANCA-associated vasculitis (AAV) due to their similarity in clinical and histological features, prognosis, and treatment. Standard therapy for patients with AAV consists of induction of remission with cyclophosphamide and glucocorticoids, followed by remission maintenance with azathioprine or methotrexate and a tapering course of glucocorticoids.1,2 Relapses of AAV occur in 50% of patients within 5 years of diagnosis, and treatment toxicity is common.3,4 Safe and effective therapies to maintain remission of AAV are a priority.

1 October 2015 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
KLKenneth Lim
Kenneth Lim
AGArnoud Groen
Arnoud Groen
GMGuerman Molostvov
Guerman Molostvov
TLTzongshi Lu
Tzongshi Lu
KLKathryn S. Lilley
Kathryn S. Lilley
DZDaniel Zehnder
Daniel Zehnder
Context: α-Klotho has emerged as a powerful regulator of the aging process. To date, the expression profile of α-Klotho in human tissues is unknown, and its existence in some human tissue types is subject to much controversy. Objective: This is the first study to characterize systemwide tissue expression of transmembrane α-Klotho in humans. We have employed next-generation targeted proteomic analysis using parallel reaction monitoring in parallel with conventional antibody-based methods to determine the expression and spatial distribution of human α-Klotho expression in health. Results: The distribution of α-Klotho in human tissues from various organ systems, including arterial, epithelial, endocrine, reproductive, and neuronal tissues, was first identified by immunohistochemistry. Kidney tissues showed strong α-Klotho expression, whereas liver did not reveal a detectable signal. These results were next confirmed by Western blotting of both whole tissues and primary cells. To validate our antibody-based results, α-Klotho-expressing tissues were subjected to parallel reaction monitoring mass spectrometry (data deposited at ProteomeXchange, PXD002775) identifying peptides specific for the full-length, transmembrane α-Klotho isoform. Conclusions: The data presented confirm α-Klotho expression in the kidney tubule and in the artery and provide evidence of α-Klotho expression across organ systems and cell types that has not previously been described in humans.

10 July 2018 in Research Involvement and Engagement
Verified
Journal Article
Open access
PDF file
LCLaura Cowley
Laura Cowley
THTess Harris
Tess Harris
SKSabine Kläger
Sabine Kläger
IWIan B. Wilkinson
Ian B. Wilkinson
THThomas F. Hiemstra
Thomas F. Hiemstra
Patients usually understand their disease and lifestyle needs better than many medical professionals. They also have important ideas about what research would be most beneficial to their lives, especially on how to manage symptoms in a way that improves daily quality of life. In the UK, the National Institute for Health Research has recognised the value of patient insight, and now requires researchers with public funding to involve patients and the public throughout the research process. There are many opportunities for involvement, but these generally focus on improving study design to ensure the trial is acceptable to participants. Some programmes work towards setting research priorities as important to patients, public members, and medical experts, but due to the complexity and cost involved in running clinical trials, the majority of research originates with the pharmaceutical industry or academic institutions. There is a clear mismatch between research ideas that patients prioritise (quality of life), and those actually investigated (drug development). The Patient Led Research Hub (PLRH) is a new initiative hosted by the Cambridge Clinical Trials Unit. The PLRH supports research ideas as proposed by patient organisations, providing resources and expertise in research design and delivery. The PLRH aims to co-produce any technically feasible project, regardless of disease or symptom focus. The proposing patient group maintains ownership of the project with an active role in study management. This method of research has proven to produce credible research studies that are of direct relevance to patients. Patient and Public Involvement has become an indispensable and expected component of healthcare research in the United Kingdom, largely driven by the National Institute of Health Research and other research funders. Opportunities for patients to become involved in research abound, and many organisations now have dedicated ‘public involvement’ teams. However, its value is often questioned amidst criticism of tokenism and the recognition that a mismatch persists between patient priorities and funded research. Although patients are frequently consulted, evidence that their involvement influences the research agenda remains limited. We propose a novel model that allows patients and the public not only to propose research questions, but to design, initiate and deliver their own research with all the necessary support from research professionals. We demonstrate the feasibility and utility of this approach in reporting the establishment, experiences and progress of the Patient Led Research Hub. Using this resource, patient organisations are now able to initiate and conduct rigorous clinical research unfettered by the constraints of academic or economic agendas.

7 June 2017 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
MMMatthew David Morgan
Matthew David Morgan
MSMatthew Szeto
Matthew Szeto
MWMichael Walsh
Michael Walsh
DJDavid Jayne
David Jayne
KWKerstin Westman
Kerstin Westman
LHLorraine Harper
Lorraine Harper
Relapse of disease is frequent in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). It is unclear whether persistent ANCA when starting maintenance therapy increases the risk of relapse. We examined the association between ANCA status and relapse in two randomised controlled trials. ANCA-positive patients in two trials, CYCLOPS and IMPROVE, were switched from cyclophosphamide to maintenance therapy after achieving clinical remission. We classified patients as being either ANCA-positive or ANCA-negative at the time they started maintenance therapy. We compared the risk of relapse in ANCA-positive and ANCA-negative patients. Of 252 patients included, 102 (40%) experienced at least one relapse during the follow-up period. At the time of the switch from induction to maintenance therapy, 111 were ANCA-positive, of whom 55 (50%) relapsed, compared to 141 patients who were ANCA-negative, of whom 47 (33%) relapsed. In multivariable time-to-event analysis, a reduced risk of relapse was associated with having become ANCA-negative at the time of switching to maintenance therapy (hazard ratio 0.63, 95% confidence interval 0.42–0.95; p = 0.026). In addition, initial proteinase 3 (PR3)-ANCA, younger age, lower serum creatinine, pulsed cyclophosphamide for remission induction, and mycophenolate mofetil for remission maintenance were all associated with an increased risk of relapse. Becoming ANCA-negative before the switch to maintenance is associated with a reduced risk of relapse. CYCLOPS: ClinicalTrials.gov, NCT00430105 . Registered retrospectively on 31 January 2007. IMPROVE: ClinicalTrials.gov, NCT00307645 . Registered retrospectively on 27 March 2006.

26 February 2015 in Nephron
Verified
Journal Article
Open access
PDF file
PGPeter A.G. Galloway
Peter A.G. Galloway
RERagada El-Damanawi
Ragada El-Damanawi
VBVictoria Bardsley
Victoria Bardsley
NPNicholas R. Pritchard
Nicholas R. Pritchard
AFAndrew C. Fry
Andrew C. Fry
THThomas F. Hiemstra
Thomas F. Hiemstra
Background/Aims: Calciphylaxis is associated with a poor prognosis in dialysis patients, and its pathogenesis remains incompletely understood. Although the use of vitamin K antagonists (VKA) has been implicated, previous reports are conflicting. We aimed to determine if vitamin K antagonists conferred an increased risk of calciphylaxis in patients on dialysis. Methods: We performed a single-centre, retrospective cohort study of 2,234 patients receiving dialysis, and compared the characteristics of those with and without calciphylaxis. Results: We identified 5 cases of calciphylaxis (all female) between January 2009 and December 2013. Overall, 142 patients (6.4%) were treated with VKA during the study period. Calciphylaxis was more common in the VKA group (4 of 142 patients, OR = 61, 95% CI 6.7-546, p = 0.0001). VKA was withdrawn in all cases and treatment instituted with sodium thiosulphate, cinacalcet and supportive measures. All patients recovered, although there was one sudden cerebrovascular death during follow-up. Conclusion: Treatment with VKA predisposes to the development of calciphylaxis.

1 April 2020 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
KLKenneth Lim
Kenneth Lim
STStephen M. S. Ting
Stephen M. S. Ting
THThomas Hamborg
Thomas Hamborg
GMGordon McGregor
Gordon McGregor
DODavid Oxborough
David Oxborough
THThomas F. Hiemstra
Thomas F. Hiemstra
Cardiovascular disease (CVD) is highly prevalent and a leading cause of death among patients with chronic kidney disease (CKD).1 Left ventricular hypertrophy and systolic and diastolic dysfunction are well-recognized indicators of worse cardiovascular outcomes in patients undergoing dialysis. In advanced CKD, the myocardium is exposed to complex metabolic stressors that result from uremia-related inflammation, oxidative stress, renin-angiotensin-aldosterone system activation, calcitriol and klotho deficiency, increased fibroblast growth factor (FGF) 23, and changes in mineral metabolism.2 This exposure leads to myocyte hypertrophy, reduced myocardial capillarization, and nonvascularized interstitial fibrosis as well as arteriosclerosis and arterial stiffening.3,4 Together, these ultrastructural changes reduce pump efficiency and increase cardiac energy expenditure and myocardial oxygen consumption.